Egalet Corporation has submitted to the FDA a supplemental new drug application (sNDA) for Oxaydo (oxycodone HCl, USP) tablets C-II...
Egalet Corporation announced top-line results from a pharmacokinetic study demonstrating bioequivalence (BE) of Oxaydo (oxycodone HCl, USP) tablets CII 15...
Egalet Corporation announced Category 1 abuse-deterrent data presented at PAINWeek 2016 demonstrate that Oxaydo (oxycodone HCl, USP) tablets CII resist...